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ABSTRACT
Glycosylation has significant effects on cancer progression. Fucosylation is one of 
the most important glycosylation events involved in hepatocellular carcinoma (HCC). 
Here, we compared N-glycan profiles of liver tumor tissues and adjacent tissues of 
27 HCC patients to reveal the association between fucosylation and HCC progression, 
as well as verified the potential role of miRNA in regulating fucosylation. Mass 
spectrometry (MS) analysis showed pronounced differences of the N-glycosylation 
patterns and fucosylated N-glycans between the adjacent and tumor tissues. Different 
fucosyltransferase (FUT) genes were also identified in adjacent and tumor tissues, 
and two HCC cell lines with different metastatic potential. High-level expression of 
FUT8 was detected in tumor tissues and highly metastatic HCC cells. Altered levels of 
FUT8 in HCC cell lines significantly linked to the malignant behaviors of proliferation 
and invasion in vitro. Furthermore, using microRNA array, we identified FUT8 as 
one of the miR-26a, miR-34a and miR-146a-targeted genes. An inverse correlation 
was revealed between the expression levels of FUT8 and these miRNAs. Luciferase 
reporter assay demonstrated these miRNAs specifically interacted with the 3′UTR of 
FUT8 and subsequently down-regulated FUT8 expression-level. The forced expression 
of these miRNAs was able to induce a decrease in FUT8 levels and thereby to suppress 
HCC cells progression. Altogether, our results indicate that fucosylated N-glycan and 
FUT8 levels can be used as markers for evaluating HCC progression, as well as miRNAs 
may be involved in inhibition of fucosylation machinery through targeting FUT8. 
INTRODUCTION
Liver cancer is the 5th most common cancer, but 
the 2nd leading cause of cancer death. Approximately 
80% of all liver cancers are hepatocellular carcinoma 
(HCC), which has very high mortality due to its poor 
early diagnosis and limited treatment. [1] Despite recent 
advances in disease management and treatment, the 
prognosis in HCC patients remains unfavorable with 
a median survival of most patients of 6–9 months after 
diagnosis [2]. Therefore, it is urgent to investigate the 
molecular mechanism of HCC so as to identify markers 
for HCC diagnosis and targets for effective therapeutic 
strategies.
Glycosylation is a common and highly diverse 
form of protein modification [3]. Altered glycosylation 
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is a hallmark of cancer that is found to occur during 
cancer progression [4, 5]. Glycans are detected in many 
cancer-associated events such as migration, adhesion, 
and metastasis [6]. Aberrant glycosylation and increased 
fucosylation are lately recognized as an indicator of 
HCC. Zhang et al. showed that the fucosylated glycans 
were upregulated in HCC serum samples versus cirrhosis 
samples [7], and the level of core-α-1, 6-fucosylated 
glycan increased both on the cell surface and in the 
serum samples of HCC patients [8]. Mehta et al. found 
that the N-linked glycans varied when comparing 
16 tumor samples and adjacent tissue of HCC [9]. 
Zhu et al. demonstrated that aberrant fucosylation of 
glycosphingolipids in HCC overexpressed in tumor tissues 
in comparison to peritumoural tissues [10]. Investigation 
of HCC-associated glycosylation changes can be vital for 
better understanding of the function of fucosylated glycans 
and fucosyltransferases (FUTs) in the progression of HCC.
FUT family is a group of fucosylation synthases. 
So far, 13 FUTs are known to be encoded in the human 
genome, i.e. FUT1 to 11, protein O-FUT 1 (POFUT1), 
and POFUT2 [11]. Forced FUT1 expression in human 
hepatocarcinoma cells led to the inhibition of tumor 
growth [12], and FUT2 expression was found increased 
in HCC cells [13]. FUT6 was highly expressed in HCC 
tissues and positively associated with the progression of 
HCC cells [14]. FUT7 was a potential anti-apoptotic factor 
in human hepatocarcinoma cells [15]. FUT8 was also up-
regulated in HCC, and associated to hepatocarcinogensis 
and poor differentiation [16, 17]. Although FUT family is 
well-known to play an important role in HCC progression, 
the underlying mechanisms of fucosylation mediated by 
miRNA remain unknown.
MicroRNAs (miRNAs) are evolutionarily conserved 
noncoding RNAs of 21–25 nucleotides in length, with 
function as critical gene regulators via negatively 
regulating the expression of target genes [18]. Recent 
studies have identified several deregulated miRNAs 
in HCC tissues or cells, and revealed their activities 
in HCC carcinogenesis and progression. Altogether 
indicates that restoration of the deregulated miRNAs 
might be considerable therapeutic strategies for HCC 
[19, 20]. Among the HCC-related miRNAs, contradictory 
relationship between miR-34a or miR-26a levels and 
HCC malignance was reported. MiR-34a expression 
was significantly decreased in HCC compared with 
those in corresponding adjacent tissues, and it was found 
associated with malignant characteristics in patients with 
HCC [21, 22]. The miR-26a expression was significantly 
down-regulated in HCC cells and HCC tissues, and 
overexpression of miR-26a promoted apoptosis of HCC 
cells [23, 24]. However, it is unclear whether miR-34a, 
miR-26a and miR-455-3p can inhibit the malignant 
behaviors of HCC cells through fucosylation mediation.
Here, we obtained the comprehensive N-glycan 
profiles and fucosylated N-glycan alteration of adjacent 
and tumor tissues from HCC patients using MALDI-
TOF-MS analysis. Expression level of FUT genes was 
measured between the tumor samples and adjacent tissues, 
and HCC cells with different metastatic potential using 
real-time PCR. In addition, miR-26a, miR-34a and miR-
146a-targeted genes were identified with microRNA array. 
This study provides new insights into HCC-associated 
fucosylated N-glycan changes and sets a miRNA-mediated 
mechanism. 
RESULTS
Comparison with N-glycans derived from HCC 
tumor and adjacent tissues
In this study, 27 HCC tumor tissues and 
corresponding adjacent tissues were applied to study the 
HCC-specific, cell-surface N-glycans by using MALDI-
TOF MS analysis. N-glycan profile spectra of HCC 
tumor and adjacent tissues were shown in Figure 1A. The 
assigned N-glycan signals were summarized in Table 1. 
The intensities of the observed MS signals were presented 
as a histogram in Figure 1B labeled with the estimated 
monosaccharide composition. The results showed that 
the N-glycan profiles of HCC tissues were substantially 
distinguished from those of the corresponding adjacent 
tissues (Figure 1A). The N-glycan profiles of HCC tumor 
and adjacent tissues were dominated by high-mannose 
type glycans (peak 4, 8, 12, 15 and 17, Table 1). The ten 
most abundant N-glycans peak 1, 5, 9, 10, 14, 16, 20, 21, 
24 and 25 were identified exclusively in tumor tissues 
(Table 1), amongst peak 1, 5, 9, 16, 20, 21, 24 and 25 were 
of fucosylated N-glycans. Peak 18 was also significantly 
increased in the tumor group (> 2 fold) compared to the 
adjacent tissue group (Figure 2B). The levels of peaks 6, 
7, 12, 15, 17, 19, 22, and 23 were significantly increased in 
the adjacent tissue group (> 2 fold) compared to the tumor 
group (Figure 2B), but only peak 22 was shown to be 
fucosylated N-glycans. Notably, the peaks corresponding 
to fucosylated oligosaccharides were often observed in 
tumor tissues.
Differential expression of FUT family in HCC 
tissues and HCC cell lines 
To increase our understanding of the regulation of 
fucosylation, the mRNA levels of FUT family were obtained 
by qRT-PCR in the HCC tumor and adjacent tissues. Our 
data demonstrated that tumor tissues contained higher 
levels of FUT4 (2.19 folds), FUT5 (1.81 folds), FUT8 
(2.76 folds), FUT11 (2.03 folds) and POFUT2 (1.55 folds) 
transcripts compared to adjacent tissues (Figure 2A). No 
significant difference was shown in the expression level of 
the other members of FUT family between the two groups 
except FUT1 (1.64 folds), FUT2 (1.58 folds) and FUT7 
(1.75 folds) high in the adjacent tissues (Figure 2A).
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Furthermore the FUT family was examined in two 
HCC cell lines. The FUT gene expression levels of the 
MHCC97H cells with high metastatic potential differed 
from cell lines MHCC97L with low metastatic potential. 
MHCC97H cells showed a remarkable increase in mRNA 
level of gene FUT4 (2.84 folds), FUT5 (2.03 folds), 
FUT6 (1.67 folds), and FUT8 (3.11 folds) (Figure 2B), 
suggesting that MHCC97H cells expressed high levels 
of fucosylation-related genes. Only slight difference was 
observed in the level of FUT1 (1.75 folds) and FUT9 
(1.58 folds) mRNA. No significant differences were found 
in the transcription level of FUT2, FUT3, FUT7, FUT10, 
FUT11, POFUT1 and POFUT2 mRNA (Figure 2B). In the 
current study FUT8 of 3.11 folds expression was chosen 
for further investigation.
FUT8 correlates with HCC cells progression 
In order to understand whether FUT8 has biological 
significance in the progression of HCC cells, highly 
metastatic MHCC97H cells were subjected to FUT8 
knockdown, while low metastatic MHCC97L cells were 
stably transfected with FUT8. Both were examined for 
tumor progression in vitro. As shown in Figure 3A, the 
expression of FUT8 was significantly decreased both in 
transcription and protein level in MHCC97H shFUT8 
transfectant compared with those in the controls. The 
higher expression levels of FUT8 were detected in 
MHCC97L FUT8 cells (Figure 3C). 
LCA lectin, which recognizes Fucα-1, 6GlcNAc 
structures (product of FUT8), was used to analyze the 
alterations in the N-glycosylation pattern of glycoproteins. 
We examined the fluorescence intensity of FITC-LCA-
lectin binding on MHCC97H and MHCC97L cells 
after FUT8 regulation using flow cytometry. Figure 3B 
showed that the FUT8 knockdown resulted in a decrease 
of α-1, 6 fucosylation level in MHCC97H shFUT8 cells. 
The fluorescence intensity on FITC-LCA also revealed 
variation of α-1, 6 fucosylation in MHCC97L FUT8 cells 
compared with those in the controls (Figure 3D). 






1 No 1345.712 Fuc+Man3HexNAc2
2 1375.708 1375.723 Hex+Man3HexNAc2
3 1416.727 1416.754 HexNAc+Man3HexNAc2
4 1579.797 1579.831 Man2+Man3HexNAc2
5 No 1590.847 HexNAcFuc+Man3HexNAc2
6 1620.824 1620.846 HexHexNAc+Man3HexNAc2
7 1661.848 1661.886 HexNAc2+Man3HexNAc2
8 1783.901 1783.936 Man3+Man3HexNAc2
9 No 1794.958 HexHexNAcFuc+Man3HexNAc2
10 No 1824.957 Hex2HexNAc+Man3HexNAc2
11 1835.969 1835.985 HexNAc2Fuc+Man3HexNAc2
12 1988.007 1988.039 Man4+Man3HexNAc2
13 2010.003 2010.062 HexNAc2Fuc2+Man3HexNAc2
14 No 2070.094 Hex2HexNAc2+Man3HexNAc2
15 2192.110 2192.152 Man5+Man3HexNAc2
16 No 2244.198 Hex2HexNAc2Fuc+Man3HexNAc2
17 2396.206 2396.254 Man6+Man3HexNAc2
18 2407.173 2407.231 Hex4HexNAcFuc+Man3HexNAc2
19 2431.223 2431.284 Hex2HexNAc2NeuAc+Man3HexNAc2
20 No 2605.378 Hex2HexNAc2FucNeuAc+Man3HexNAc2
21 No 2693.424 Hex3HexNAc3Fuc+Man3HexNAc2
22 2768.339 2768.398 Hex4HexNAcFucNeuAc+Man3HexNAc2
23 2792.423 2792.448 Hex2HexNAc2NeuAc2+Man3HexNAc2
24 No 2966.557 Hex2HexNAc2FucNeuAc2+Man3HexNAc2
25 No 3054.615 Hex3HexNAc3FucNeuAc+Man3HexNAc2
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As expected, cell counting kit-8 (CCK-8) 
assays revealed that knockdown of FUT8 repressed 
MHCC97H shFUT8 proliferation (Figure 3E). Inversely, 
overexpression of FUT8 promoted MHCC97L FUT8 cells 
proliferation (Figure 3G). We next assessed the effect of 
FUT8 on cell migration and invasion. Down-regulation 
of FUT8 using shRNA resulted in a significant decrease 
in the migratory and invasive capabilities of MHCC97H 
shFUT8 cells (Figure 3F), and overexpressing FUT8 
in MHCC97L resulted in a significant increase in the 
percentage of migratory and invasive cells (Figure 3H). 
Overall our results demonstrated that FUT8 indeed 
mediated tumor cells progression in vitro through 
modifying the N-glycosylation profile in terms of Fucα-1, 
6GlcNAc structures in HCC cells.
MiR-26a, miR-34a and miR-455-3p directly 
target FUT8 
Recent studies have linked tumor progression to 
the altered expression of miRNAs. We first screened the 
expression profiles of human miRNAs in MHCC97H 
and MHCC97L cell lines using microRNA array 
(Kangchen, Shanghai, China). The studies indicated that 
3 microRNAs (miR-26a, miR-34a, and miR-455-3p) 
were down-regulated by at least 2 fold in the MHCC97H 
cells compared to those in the MHCC97L cells. To 
explore and confirm the findings from our microRNA 
array analysis, we examined the expression levels of 
miRNAs in HCC cell lines and HCC samples by qRT-
PCR. The results in Figure 4A show remarkably lower 
levels of miR-26a, miR-34a, and miR-455-3p in 27 HCC 
tissues than in adjacent tissues. These miRNAs were 
also underexpressed in MHCC97H cells compared to 
those in MHCC97L cells and L02 cells (Figure 4B). This 
suggested that down-regulation of miR-26a, miR-34a, 
and miR-455-3p might be involved in the progression 
of HCC. We then examined the relationship between 
miR-26a, miR-34a, miR-455-3p and FUT8 expression 
in 27 HCC tissue samples by qRT-PCR. As shown in 
Figure 4C, the FUT8 mRNA expression appeared to 
be inversely correlated with the levels of miRNAs 
(P < 0.05), which was consistent with HCC cell lines. 
FUT8 mRNA was also overexpressed in 27 HCC tissues 
compared to adjacent tissues (Figure 4D).
Next, we investigated whether the 3′UTR of FUT8 
is a direct target of miR-26a, miR-34a, and miR-455-3p. 
To do so, the complementary sequence to miR-26a, miR-
34a, or miR-455-3p seed sequence of FUT8 3′-UTR (wt 
3′-UTR) was cloned into a luciferase reporter vector. In 
parallel, we mutated the 3′UTR of FUT8 (mut 3′-UTR) 
complementary to the miR-26a, miR-34a, or miR-455-3p 
seed sequence in the same reporter plasmid. HEK-293 cells 
were then transfected with wt or mut FUT8-3′UTR vector 
and miR-26a, miR-34a, or miR-455-3p mimics. Forced 
miRNAs expression decreased luciferase activity, and this 
suppression was reversed by the mutation of the target 
sequences in the 3′-UTRs of FUT8 (Figure 4E–4G). 
Figure 1: The profiles of N-Glycan composition in HCC tumor and adjacent tissues. (A) MALDI-TOF MS spectra of 
N-glycans from HCC tumor and adjacent tissues were shown respectively. N-glycans were released by PNGase F and permethylated. (B) 
Histograms of relative intensities of the differential N-glycan signals were observed (the histograms represents only signal intensities but 
not the quantities). The signals indicated with Arabic numerals are summarized in Table 1. 
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We further transfected MHCC97H cells with 
miR-26a, miR-34a, or miR-455-3p mimics, MHCC97L 
cells with inhibitor and measured the changes in FUT8 
expression levels. Overexpression of miR-26a, miR-34a, 
or miR-455-3p remarkably reduced FUT8 expression both 
mRNA and protein levels in MHCC97H cells (Figure 4H). 
Conversely, knockdown of miR-26a, miR-34a, or 
miR-455-3p increased the expression level of FUT8 in 
MHCC97L cells (Figure 4I). Taken together, these results 
suggest that miR-26a, miR-34a, and miR-455-3p directly 
bind and negatively regulate FUT8 mRNA stability.
MiR-26a, miR-34a and miR-455-3p regulate 
HCC progression by targeting FUT8 
Since miR-26a, miR-34a and miR-455-3p targeted 
FUT8, we further investigated whether these miRNAs 
modulated HCC progression and the underlying 
mechanisms. As shown in Figure 5A, mimics of these 
miRNAs strongly up-regulated miR-26a, miR-34a and 
miR-455-3p expression in MHCC97H cells. The effect of 
miRNAs overexpression markedly inhibited MHCC97H 
cells proliferation and colony formation efficiency (Figure 
5B, 5C). Because Ki67 antigen is an important marker of 
cell proliferation, we next examined Ki67 expression by 
immunofluorescence analysis. The staining results showed 
that the overexpression of miRNAs in MHCC97H cells 
significantly down regulated Ki67 staining (Figure 5D). 
We next assessed the effects of miRNA on MHCC97H cell 
migration and invasion. Overexpression of miR-26a, miR-
34a and miR-455-3p significantly decreased the migration 
and invasion abilities of MHCC97H cells (Figure 5E).
Anti-miRNAs were transfected into MHCC97L 
cells followed by qRT-PCR and western blot analysis. 
As shown in Figure 6A, inhibitor of these miRNAs 
decreased the expression of miR-26a, miR-34a and miR-
455-3p in MHCC97L cells. CCK-8 assays revealed that 
MHCC97L cells in the miRNA inhibitor groups had 
higher proliferative ability than controls (Figure 6B). The 
colony formation and Ki67 expression were also increased 
in the miRNA inhibitor groups (Figure 6C, 6D). Matrigel 
invasion and migration assays were also performed, 
and exogenously downregulation of miRNA expression 
increased the number of invasive and migratory cells 
significantly (Figure 6E).
To further determine whether miRNAs regulated 
MHCC97H cells tumorigenesis by targeting FUT8, we 
assessed the effects of miRNA mimics on MHCC97H cells 
Figure 2: Differential expression of FUT family in HCC tissues and HCC cell lines. The mRNA levels of FUT family were 
analyzed by qRT-PCR. (A) Tumor tissues expressed higher levels of FUT4, FUT5, FUT8, FUT11 and POFUT2 mRNA than adjacent tissues. 
(B) MHCC97H cells with high metastatic potential expressed higher levels of FUT4, FUT5, FUT6 and FUT8 mRNA than MHCC97L cells 
with low metastatic potential. Data are the means ± SD of triplicate determinants.
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xenograft formation. MHCC97H cells were transfected with 
miRNA mimics or NC mimic and implanted subcutaneously 
into the right flank of each nude mouse respectively (n = 
6). One week later, the mice were intratumorally injected 
with mimic control or miR mimic three times per week for 
three weeks. Tumor sizes were measured with weekly after 
implantation. The result showed significantly reduced tumor 
volume and weight in miR-26a, miR-34a or miR-455-3p 
mimic expressing xenografts as compared to controls 
(p < 0.05) (Figure 7A). Consistent with the in vitro assay, 
we demonstrated that miR-26a, miR-34a and miR-455-3p 
significantly reduced the protein levels of FUT8 and Ki67 
in the tumor tissues (Figure 7B).
DISCUSSION
Representing the third class of biomacromolecules, 
glycans are becoming increasingly important in 
Figure 3: FUT8 correlates with HCC cells progression in vitro. (A) FUT8 transcript was decreased apparently in MHCC97H 
cells by shRNA treatment. The distinct reduction of FUT8 was observed at mRNA and protein levels by qRT-PCR and western blot analysis 
(*P < 0.05). (B) Differential FITC-LCA binding profiles of MHCC97H control and MHCC97H shFUT8 cell lines using flow cytometry. 
Histograms of fluorescence intensities of cells with specific carbohydrate expression as determined. (C) After full-length sequences 
transfection, FUT8 mRNA and protein levels were increased notably in MHCC97L cells by qRT-PCR and western blot analysis (*P < 0.05). 
(D) Flow cytometry analysis showed α-1, 6 fucosylation level detected by FITC-LCA on the cell surface, was also increased in MHCC97L 
FUT8 cells. (E) Growth curves of MHCC97H shFUT8 cells were compared to control cells with the CCK-8 assay. (F) Transwell cell 
migration and invasion assays were performed to compare cell migration and invasion between MHCC97H shFUT8 cells and MHCC97H 
control. (G) Growth curves of MHCC97L FUT8 cells were compared to control cells with the CCK-8 assay. (H) In vitro Transwell cell 
migration and invasion analysis was performed. MHCC97L FUT8 cells were significantly more migratory and invasive (*P < 0.05) than 
MHCC97L mock cells. Data are the means ± SD of triplicate determinants (*P < 0.05).
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biological, chemical and clinical research and 
applications. Enhanced fucosylation has been proposed 
as a marker of the progression from liver disease to 
HCC. In the current study, we analyzed the characteristic 
N-linked profiling pattern and fucosylated N-glycan in 
HCC tissue samples. We further examined expression 
of FUT family, which was reported to be associated 
with tumor progression. We also showed that negative 
regulators of FUT8, such as miR-26a, miR-34a and 
miR-455-3p, could reduce FUT8-mediated progression 
in HCC.
Altered expression of N-glycans has been observed 
by MS in many types of tumor cells. MS technology 
as a novel methodology provides highly sensitive and 
rapid glycan analysis. Holst et al. have shown noticeable 
differences between the N-glycosylation patterns of 
25 different colorectal cancer cell lines, as well as 
between the patterns of colorectal tumor tissues and 
corresponding control tissues from 13 colorectal cancer 
patients by MALDI-TOF (/TOF)-MS analysis [25, 26]. 
Recent studies quantitatively profiled N-linked glycans 
from human serum of healthy controls and ovarian 
Figure 4: MiR-26a, miR-34a and miR-455-3p as negative regulators of FUT8. (A) miR-26a, miR-34a and miR-455-3p 
expression were significantly decreased in 27 HCC compared with the corresponding adjacent tissues using qRT-PCR analysis. (B) The 
expression of miR-26a, miR-34a and miR-455-3p was examined by qRT-PCR in the MHCC97H, MHCC97L and L02 cell lines. (C) 
Relationship between miR-26a, miR-34a and miR-455-3p levels and FUT8 mRNA expression in 27 HCC tumor and 27 adjacent tissues. 
(D) FUT8 expression was significantly increased in 27 HCC compared with the corresponding adjacent tissues using qRT-PCR analysis. 
(E–G). The nucleotides sequence of the target site of miRNAs in FUT8 3′-UTR was shown; Luciferase assay for the direct targeting of 
3′-UTR of FUT8 by miR-26a, miR-34a and miR-455-3p. The wide-type and mutant miRNA target sequences of FUT8 were fused with 
luciferase reporter and transfected into 293T cells, transfected with miRNA mimic and NC mimic. The mean of the results from the cells 
transfected with the NC mimic was set at 100. Each bar represents the relative luciferase activity (*P < 0.05). (H) FUT8 was analyzed by 
qRT-PCR and western blot in MHCC97H cells treated with miR-26a, miR-34a and miR-455-3p mimic (*P < 0.05). (I) FUT8 was analyzed 
by qRT-PCR and western blot in MHCC97L cells treated with miR-26a, miR-34a and miR-455-3p inhibitor (*P < 0.05). Data are the 
means ± SD of triplicate determinants.
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cancer patients by MALDI-TOF/MS and provided 
critical information on tumor biomarkers for screening 
of ovarian cancer [27]. In an effort to identify the altered 
patterns, we applied MALDI-TOF-MS to profile total 
N-glycans in HCC tissues and adjacent tissues, and 
found dramatic differences in N-glycans between these 
two groups. This result corresponded with our findings 
of differential N-glycan composition in human HCC cell 
lines MHCC97H and MHCC97L with different metastatic 
potential by MS analysis [28]. Furthermore, MALDI-
TOF-MS analysis of N-glycan profiles demonstrated 
increased fucosylated N-glycan in HCC tissues. Other 
researchers have also observed increased levels of core 
and outer-arm fucose residues in the serum of patients 
with HCC [29] and HCC tissues [30]. Overall, observation 
of the tendency toward enhanced fucosylation would be 
important in the monitoring of tumor progression. 
Increasing studies demonstrate that the alterations of 
fucosylation and the levels of fucosyltransferases activities 
derived from the malignant transformation are relevant 
to tumor progression and metastasis [31–34]. In the 
present study, the results indicated that the FUT profiling 
patterns were significantly different in HCC tissues to 
adjacent tissues. Among these the expression of FUT4, 
FUT5, FUT8, FUT11 and POFUT2 was significantly up-
regulated in HCC tissues compared to adjacent tissues, and 
FUT8 was the most expressed on HCC tissues. As shown 
in recent research, the FUT8 mRNA level was significant 
higher in 24 pairs of HCC tissues than that in their 
corresponding adjacent non-tumor liver tissues [35]. In 
addition, the expression profiles of FUT gene family were 
shown to be remodeled in HCC cell lines. MHCC97H 
cell with high metastatic potential was characterized of 
higher levels of FUT4, FUT5, FUT6 and FUT8, while 
MHCC97L cell with low metastatic potential expressed 
more FUT1 and FUT9. FUT8 level was also found to be 
up-regulated in high metastatic potential HCCLM3 cells 
(HCC cell lines) in comparison to Hep3B cells [36]. Our 
results showed a significant correlation between N-glycan 
traits derived from MS-data and corresponding FUT 
mRNA levels that involved in the synthesis of fucosylated 
glycans.
FUT8 was strongly correlated with the presence 
of HCC tissues and HCC cells, and thus we speculated 
Figure 5: Effect of miR-26a, miR-34a and miR-455-3p mimic on cell progression in MHCC97H cells. (A) The expression of 
miR-26a, miR-34a and miR-455-3p was studied by qRT–PCR in MHCC97H cells transfected with the mimics (*P < 0.05). (B) Transfection 
of miR-26a, miR-34a and miR-455-3p mimic in MHCC97H cells inhibited cellular viability as revealed by CCK-8 assay (*P < 0.05). (C) 
Overexpression of miR-26a, miR-34a and miR-455-3p inhibited the growth of MHCC97H cells with in focus formation assay. (D) Ki67 
expression was detected by immunofluorescence staining in MHCC97H cells treated with miRNA mimic transfection. Red fluorescence: 
Ki67; DAPI staining for nuclear DNA. (E) Transwell cell migration and invasion assays were used to compare cell migration and invasion 
between miRNA mimic- and NC mimic-transfected cells. The data were mean ± S.D. of three separate transfections (*P < 0.05).
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Figure 6: Effect of miR-26a, miR-34a and miR-455-3p inhibitor on cell progression in MHCC97L cells. (A) The 
expression of miR-26a, miR-34a and miR-455-3p was studied by qRT–PCR in MHCC97L cells transfected with the inhibitor (*P < 0.05). 
(B) MHCC97L cells were transfected with miR-26a, miR-34a and miR-455-3p respectively. Expression of miRNA was confirmed by qRT–
PCR. B, Growth curves of miRNA inhibitor-transfected cells were compared to NC inhibitor cells with the CCK-8 assay (*P < 0.05). (C) 
Morphology foci were observed at the microscope and photographed. (D) Ki67 expression was detected by immunofluorescence staining 
in MHCC97L cells treated with miRNA inhibitor transfection. Red fluorescence: Ki67; DAPI staining for nuclear DNA. (E) Knockdown 
of miR-26a, miR-34a and miR-455-3p significantly increased the migration and invasion of MHCC97L cells. The data were mean ± S.D. 
of three separate transfections (*P < 0.05).
Figure 7: MiR-26a, miR-34a and miR-455-3p mediates MHCC97H cells tumorigenesis by targeting FUT8. (A) 
MHCC97H cells were transfected with miRNA mimics or NC mimic and implanted subcutaneously into the right flank of each nude mouse 
respectively (n = 6). One week later, the mouse in groups were injected intratumorally with miRNA mimics or NC mimic three times per 
week for 3 weeks respectively. miR-26a, miR-34a and miR-455-3p inhibited the tumorigenesis of MHCC97H cells in vivo. The tumor 
volumes and weight were reduced in miRNA mimic groups to compare with NC mimic group (*P < 0.05). (B) The expression levels of 
Ki67 and FUT8 were analyzed by IHC in tumors. 
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that FUT8 was a key factor in promoting malignant 
progression of HCC. In order to better understand the links 
between FUT8 and HCC progression, we further regulated 
FUT8 expression. FUT8 product decreased remarkably in 
MHCC97H shFUT8 cells, but increased in MHCC97L 
FUT8 cells labeled with FITC-LCA lectin. Furthermore, 
altered levels of FUT8 were shown to be involved in 
the proliferation, migration and invasion of MHCC97H 
and MHCC97L cells in vitro. Our results suggested that 
up-regulation of FUT8 was HCC progression-related. 
Altered FUT8 expression has impact on the remodeling 
of cell surface glycoproteins oligosaccharides, which may 
consequently affect the biological functions of tumor cells. 
Other findings demonstrated FUT8 were associated with 
advanced tumoral stage of HCC. Therefore FUT8 was 
implicated as a prognostic marker and therapeutic target 
for HCC [35, 37].
It is now recognized that the aberrant expression 
of various microRNAs is closely related to the clinical 
outcomes of several human cancers, including HCC. 
MiR-34a and miR-26a have been reported as one of 
the multicentric HCC-related miRNAs [21, 22, 23, 24]. 
Differentially expressed miR-455-3p has been evaluated in 
basal cell carcinoma (BCC) of the skin [38]. In this study, 
miR-34a, miR-26a and miR-455-3p were down-regulated 
in human HCC tissues compared with in adjacent tissues. 
Accordingly we also discovered that the expression of 
these miRNAs was reduced in MHCC97H cells compared 
with MHCC97L cells. Further experiments demonstrated 
that the regulated levels of miR-34a, miR-26a and miR-
455-3p were demonstrated to be correlated with HCC cells 
progression both in vitro and vivo. Our data confirmed that 
miR-34a, miR-26a and miR-455-3p might act as tumor 
suppressors through regulating HCC cell progression. 
Recent literature have shown that miRNAs as 
important regulators of glycosylation [39] can be used as 
a proxy to define the biological functions of glycosylation 
enzymes [40]. Vaiana et al. showed that MGAT4A 
(Nacetylglucosaminyltransferase) was significantly 
altered in response to miR-424 in breast cell lines [41]. 
Moreover GalNAc transferase, GalNT7 was a target for 
miR-30 family, and ectopic expression of miR-30b/30d 
modulated the metastatic behavior of melanoma cells by 
directly targeting its enzyme activity [42]. In this study, 
our data con firmed the negative correlation between miR-
34a, miR-26a and miR-455-3p downregula tion and FUT8 
upregulation. FUT8 has been validated as a direct target 
of miR-34a, miR-26a and miR-455-3p, in HCC tissues 
and HCC cell lines. These results corresponded to those 
results from Bernardi et al. who reported that ectopic 
expression of miR-34a was able to significantly decrease 
FUT8 levels and miRNAs were involved in the regulation 
of fucosylation machinery in HCC [43]. Interestingly, 
we also revealed that low expression of miR-34a, miR-
26a and miR-455-3p, and high expression FUT8 were 
significantly associated with aggressive progression of 
human HCC cells. Functionally, these miRNAs were found 
to be involved in the development and progression of HCC 
through sup pressing the expression of FUT8. These results 
not only verify the suppression effect of these miRNAs, 
but also suggest that the miRNAs combined with FUT8 
might have a therapeutic potential for HCC treatment.
In conclusion, the current study showed that the 
N-glycan profiles and elevated fucosylation on the HCC 
tissues. The FUT family was found significantly different 
in transitional and tumor tissues, and two HCC cell lines 
with distinct metastatic potential. FUT8 was regarded as 
a potential target for HCC progression. The underlying 
mechanism was unraveled that the interaction between 
FUT8 and miR-34a, miR-26a and miR-455-3p led to 
fucosylation downregulation and subsequently HCC 
progression inhibition. Therefore FUT8/miRNAs pathway 
might be an ideal target for therapeutic intervention in 
HCC patients.
MATERIALS AND METHODS
Patients and tissue samples 
The study and its informed consent have been 
examined and certified by the Ethics Committee of the 
First Affiliated Hospital of Dalian Medical University. 
Before collecting tumor specimens written informed 
consent was acquired from each enrolled patient. All 
specimens were handled anonymously according to the 
ethical and legal regulations.
Human primary HCC and adjacent tissues (3 cm 
from the tumor edge) were extracted from the same 
27 patients who underwent surgical resections from June 
2013 to April 2015 at the First Affiliated Hospital of 
Dalian Medical University (Dalian, China). The patients 
consisted of 19 men and 8 women, with age ranging 
from 19 to 78 years (mean age of 51.3 years). None of 
the patients received any chemotherapy or radiation 
treatment prior to the surgery. All samples were confirmed 
with pathological diagnosis and classified according to 
the 2012 hepatocellular carcinomas staging system of the 
International Union against Cancer (UICC). All samples 
were snap-frozen and stored in liquid nitrogen after 
collection. The clinicopathological factors of HCC are 
summarized in Table 2.
Preparation of N-glycans 
Human primary HCC or adjacent tissues of 
27 patients were assigned randomly into three groups, 
respectively (n = 9). The samples of per group were 
pooled. Membrane proteins were extracted from the three 
groups of tumor sample or three groups of adjacent tissue 
suspension using a CelLytic MEM Protein Extraction 
kit (Sigma, St Louis, MO, USA). The membrane protein 
concentration was measured with a Micro BCA Protein 
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Assay kit (PIERCE, Rockford, IL). For releasing of 
N-glycans, 100 μg aliquots of lyophilized cell membrane 
proteins were first digested with trypsin (10 μg) and 
chymotrypsin (10 μg) dissolved in 25 mM ammonium 
bicarbonate (25 μL) at 37°C for 18 h. The digest was 
left in a water bath (85°C, 5 min) and after cooling 
N-linked oligosaccharides were released from peptides by 
treatment with PNGase F enzyme (2 μL; 6 U) at 37°C for 
18 h followed by Pronase digestion (10 μg) at 37°C for 
8 h. During the incubation time, the reaction sample was 
mixed occasionally. The released N-glycans were purified 
using an Oasis HLB cartridge (60 mg/3ml; Waters) and 
then were lyophilized. Permethylation was performed by 
using the solid NaOH technique. 
MALDI-TOF-MS analysis of permethylated 
N-glycans
 For MS analysis, the dried permethylated sample 
was resuspended in 10 μL of acetonitrile. A total of 0.5 μL 
of matrix solution (10 mg of 2, 5-DHB dissolved in 
1 mL of 30% ethanol) and 0.5 μL of the diluted analyte 
solution were spotted on the MALDI target plate (Bruker 
Daltonics). Then the plate was analyzed by MS, whose 
spectra were obtained from Na+ adduct ions. MALDI-
TOF-MS spectra were acquired using an UltrafleXtremeTM 
mass spectrometer in the positive-ion reflector mode, 
controlled by FlexControl 3.4 software Build 119 
(Bruker Daltonics). Monosaccharide compositions were 
determined by blasting against database GlycoMod: http://
www.expasy.ch/tools/glycomod/.
Cell culturation and transfection 
Human hepatocarcinoma cell lines MHCC97H, 
MHCC97L and human normal liver cell line L02 were 
purchased from the KeyGEN Company (Nanjing, China). 
MHCC97H and MHCC97L cell clones of the same genetic 
background but with different metastatic potential. The three 
cell lines were grown in 90% Dulbecco Modified Eagle’s 
Table 2: Clinicopathological characteristics of HCC patients
Characteristics n
Group
 Cancer tissues 27





 ≥ 50 17










Serum AFP level (μg/L)
 ≥ 200 18








Medium (DMEM, Gibco) supplemented with antibiotics 
(1× penicillin/streptomycin 100 U/ml, Gibco) and 10% heat-
inactivated fetal bovine serum (FBS, Gibco). The cells were 
incubated in a humidified atmosphere of 5% CO2 at 37°C. 
shRNA against FUT8, scrambled shRNA, miRNA-
34a/miR-26a/miR-455-3p/ normal control (NC) mimics, 
and miRNA-34a/miR-26a/miR-455-3p/NC inhibitors were 
chemically synthesized by Shanghai GenePharmaCo.,Ltd. 
(Shanghai, China). MHCC97H and MHCC97L cells were 
transfected with miRNAs (100 nM, the cell transfection 
efficiency was 72.3% ~78.5%) or shRNAs (50 nM, the cell 
transfection efficiency was 76.1%) using Lipofectamine 
2000 Transfection Reagent (Invitrogen).
RNA extraction and quantitative real-time PCR 
analysis 
Total RNA was isolated from frozen tissues and 
HCC cell lines, using the RNeasy Mini Kit (QIAGEN, 
valencia, CA), and cDNA was synthesized using QuantiTect 
Reverse Transcription Kit (QIAGEN, valencia, CA) 
according to the manufacturer’s protocol. The expression 
of miRNAs was determined by using mirVanaTM qRT-
PCR microRNA Detection Kit (Ambion Inc., Austin, TX, 
USA) and normalized using the 2-ΔΔCT method relative to 
U6-small nuclear RNA. FUT mRNAs were quantified with 
SYBR-Green-quantitative real-time PCR Master Mix kit 
(Toyobo Co., Osaka, Japan) and normalized to GAPDH, 
respectively. The expression level of target genes was 
determined by using Biosystems 7300 Real-Time PCR 




). All assays were triplicated independently. 
The sequences of primers were as shown Table 3.
Western blot analysis 
20 μg for each sample were run on a 10% SDS-
PAGE and then transferred a polyvinylidene difluoride 
membrane (Pall Corporation). The membrane was blocked 
with 5% non fat dry milk in PBS containing 0.1% Tween 
20 (PBST) for one hour and then probed with anti-FUT8 
monoclonal antibody (Abcam, Cambridge, UK, 1:1000 
dilution), or anti-GAPDH rabbit polyclonal antibody 
(Santa Cruz Biotech, Santa Cruz, CA, 1:1000 dilution). 
Detection was achieved using a secondary anti-rabbit 
HRP-conjugated IgG (Santa Cruz Biotech, Santa Cruz, 
CA, 1:1000 dilution). GAPDH was used as a control. 
Immunoreactive bands were visualised using ECL Western 
blotting kit (Amersham Biosciences, UK) and were 
normalized to those of GAPDH. 
Flow cytometry analysis 
Cells were collected and washed thrice with 
PBS, and then centrifuged at 1000 r/min for 5 min in 
a 1.0 mL eppendorf tube. The cells were blocked in 
2% BSA in PBS for 30 minutes and washed two times 
with PBS. After incubation of cells with fluorescein 
isothiocyanate (FITC)-LCA at a final concentration 
(10 μg/ml) in the dark for 40 min at room temperature, 
residual unbound FITC-LCA was then discarded by 
repeat centrifugation of samples at 1000 r/min. After 
removal of supernatant, cells were resuspended in 
0.2 ml PBS. The control, which was negative, cells 
and FITC-LCA was alone. Cells were collected and 
analyzed with Flow Cytometer (BD FACSAria, San 
Diego, CA, USA). Experiments were repeated at least 
3 times with similar results each time. 
Cell counting kit-8 (CCK-8) assays 
The cell proliferation assays were performed using 
cell counting kit-8 (CCK-8; KeyGEN, Nanjing, China) 
according to the manufacturer’s instruction. Cells (1 × 103/
well) were seeded in 96-well plates with 100 μl of DMEM 
medium containing 10% FBS and cultured in a humidified 
incubator (at 37°C, 5% CO2) for 24, 48 and 72 hrs, Then, 
each well was added 10 μl CCK-8 solutions at 37°C for 2 
hrs. The absorbance at 450 nm was immediately measured 
using a microplate reader. Each experiment was performed 
at least 3 times. 
Focus formation assay 
Effect of miRNA mimic or inhibi tor on foci 
formation abilities of the HCC cells was assessed by 
focus formation assays. The assay was applied in 6-well 
plates. Cells (1 × 103) were trypsinized to single-cell 
suspension and placed in triplicate onto plastic culture 
dishes in DMEM containing 10% FBS. The cultures 
were maintained in the same medium, with medium 
changes every 3 days, until the appearance of foci from 
transformed cells was evident (7 days after transfection). 
Then the colonies were counted with crystal violet 
staining. 
Immunofluorescence analysis 
Cells were transfected with miRNA mimic or 
miRNA inhibi tor as described in above. Cells were 
fixed with cold 4% formaldehyde for 10 min at room 
temperature and subsequently washed three times with 
PBS. Then, the cells were permeabilized with PBS 
containing 0.3% triton X-100 and 2% BSA for 30 minutes 
at room temperature. The cells were incubated with 
primary antibody against Ki67 (Abcam, Cambridge, 
MA, USA) overnight at 4°C. After washing with PBS, 
cells were incubated with secondary antibody. The cells 
were washed with PBS and incubated with 1 μg/mL of 
4, 6-diamino-2-phenylindole (DAPI, Sigma-Aldrich, 
St Louis, MO, USA) for nuclear staining. Images were 
generated on a fluorescence microscope (OLYPAS).
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Cell invasion and migration assays 
The invasion abilities of human HCC cells 
transfected with FUT8 shRNA/control shRNA, miR-34a/
miR-26a/miR-455-3p/NC mimic or miR-34a/miR-26a/ 
miR-455-3p/NC inhibi tor were tested by invasion assays, 
respectively, using 24-well transwell units (Corning, NY, 
USA) with 8μm pore size polycarbonate filter coated with 
ECMatrix gel (Chemicon) to form a continuous thin layer. 
Cells (4 × 104) were harvested in serum-free DMEM and 
added to the upper chamber. The lower chamber contained 
500 μl DMEM with 10% (vol/vol) FBS. The cells were 
incubated at 37°C, 5% CO2 incubator for 24 h. At the 
end of incubation, the invaded cells at the reverse side of 
the insert were fixed in methanol and were stained with 
Wright-Giemsa. The number of invaded cells on the lower 
side of the membrane was counted at 400× magnification 
from ten different fields of each filter. The migration 
assay was conducted following the aforementioned steps, 
except for the absence of the Matrigel, and 4 × 104 cells 
were added to the upper chamber. Each experiment was 
performed in triplicate and repeated 3 times.
Tumor xenograft models 
Five-week-old female athymic nude mice were 
obtained from Animal Facility of Dalian Medical 
University, and used for subcutaneous tumor implantation. 
Approximately 1 × 107 cells were inoculated subcutaneously 
into the right flank of each nude mouse, respectively. One 
week later, the mice were injected intratumorally with miR-
26a/miR-34a/miR-455a mimics or mimic control three 
times per week for 3 weeks respectively. Measurements of 
tumor size began in the first week of postinoculation and 
monitored weekly by measuring the perpendicular tumor 
diameters, length (L) and width (W), with a vernier caliper. 
Mice were killed under anesthesia 4 week after injection. 
Mice were sacrificed and their tumors were isolated, 
photographed and weighed. Tumor size was measured 
using calipers and recorded following the formula: (length 
× width2)/2.
Immunohistochemical (IHC) analysis 
After the xenograft tumor being harvested, it was 
immediately fixed in 4% paraformaldehyde, dehydrated 
in a graded series of alcohol, and then embedded in 
paraffin. 5 μm sections were sliced, dried, deparaffinized, 
rehydrated and then were immersed in 3% hydrogen 
peroxide for 10 min to block endogenous peroxidase. 
After consecutive washing with PBS, the slices were 
incubated with primary anti FUT8 or Ki67 antibody 
(1:200, Abcam, Cambridge, UK) at 4°C overnight. The 
secondary streptavidin-HRP-conjugated antibody staining 
(Santa Cruz Biotech, Santa Cruz, CA) was performed at 
room temperature for 60 min. Finally, the sections were 
Table 3: qRT-PCR conditions and primer sequences for analysis of gene expression
Gene Primer Amplicon
FUT1 5′-AAAGCGGACTGTGGATCT-3′; 5′-GGACACAGGATCGACAGG-3′ 168 bp
FUT2 5′-CTGCCCAACCACTCTGTC-3′; 5′-CCGTAAAGACAAAGAGGATG-3′ 117 bp
FUT3 5′-CAACAGAGAAAGCAGGCA-3′; 5′-AAGAAACACACAGCCACC-3′ 191 bp
FUT4 5′-TCCTACGGAGAGGCTCAG-3′; 5′-TCCTCGTAGTCCAACACG-3′ 134 bp
FUT5 5′-ATGGCAGTGGAACCTGTC-3′; 5′-GCACCATCTCTGAGCAGC-3′ 148 bp
FUT6 5′-CATTTCTGCTGCCTCAGG-3′; 5′-GGGCAAGTCAGGCAACTC-3′ 138 bp
FUT7 5′-CCACGATCACCATCCTTG-3′; 5′-AGGCTTCGGTTGGCACTC-3′ 118 bp
FUT8 5′-TCTAGCCGAGAACTGTCC-3′; 5′-GCTGCTCTTCTAAAACGC-3′ 154 bp
FUT9 5′-AAATCCCATGCAGTTCTG-3′; 5′-AAACAAGTGCTCAATGCC-3′ 124 bp
FUT10 5′-ATCTTGCCTGTGCGTCAC-3′; 5′-ATGCGTAGGTGCTTCCTC-3′ 142 bp
FUT11 5′-CTCTTGGCTTTCTTGTCC-3′; 5′-ATGACGGAGTGATTGTTC-3′ 167 bp
POFUT1 5′-AGATTCATGCCCACCTTGT-3′; 5′-GCTGTAGCCCACACACTGC-3′ 140 bp
POFUT2 5′-TTCACGACCACTATGGAGG-3′; 5′-CGGAGCCCAGCTTGACCTT-3′ 171 bp
GAPDH 5′-CTCCTCCACCTTTGACGCTG-3′; 5′-TCCTCTTGTGCTCTTGCTGG-3′ 175 bp
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counterstained with hematoxylin and cover-slipped. The 
Image-ProPlus 4.5 Software (Media Cybernetics, USA) 
was used to analyze the expression of proteins.
Luciferase assays 
A pmirGLO Dual-Luciferase miRNA Target 
Expression Vector was chosen for 3′UTR Luciferase 
assays (Promega, Madison, WI, USA). The vector 
contained firefly luciferase (luc2) used as primary reporter 
to monitor mRNA regulation and Renillaluciferase 
(hRlucneo) acting as a control reporter for normalization 
and selection. The vector could be used to study the 
influence of miRNAs on transcript stability and activity by 
the insertion of miRNA target sites 3′ untranslated region 
(UTR) of gene. The wild-type FUT8 and mutant FUT8 3′-
UTR were specifically synthesized (Promega) and inserted 
into the vector. HEK 293T cells of 50% confluence were 
seeded (5 × 104 cells per well) in a 24 well dish and were 
transfected using Lipofectamine 2000. The miRNA mimic 
or NC mimic with pmirGLO-FUT8 3′-UTR wt vector, 
pmirGLO-FUT8 3′-UTR mut vector or empty vector 
were co-transfected per well. Luciferase assays were 
performed up to 48 h after transfection by using the dual 
luciferase reporter assay system (Promega) according to 
the manufacturer’s protocol. Firefly and Renilla luciferase 
activities were measured and normalized to Renilla 
luciferase. The mean of relative luciferase activities from 
the cells transfected with the empty vector and NC mimic 
was set at 100. The results were presented as the mean 
value ± SD for three repeat experiments.
Statistical analysis 
Each experiment was performed at least in 
triplicate, and the measurements were performed in 
three independent experiments. Data are expressed as 
means ± standard deviation (SD). Student’s t-test was 
used to compare the means of two groups. P < 0.05 was 
considered statistically significant. All analyses were 
performed using SPSS 17.0 statistical packages (SPSS 
Inc., Chicago, IL).
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